Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson's Disease.
Parkinson's disease (PD) is a common neurodegenerative disorder that primarily afflicts the elderly. It is characterized by motor dysfunction due to extensive neuron loss in the substantia nigra pars compacta. There are multiple biological processes that are negatively impacted during the pathogenesis of PD, and are implicated in the cell death in this region. Neuroinflammation is evidently involved in PD pathology and mitigating the inflammatory cascade has been a therapeutic strategy. Age is the number one risk factor for PD and thus needs to be considered in the context of disease pathology. Here, we discuss the role of neuroinflammation within the context of aging as it applies to the development of PD, and the potential for two representative compounds, fractalkine and astaxanthin, to attenuate the pathophysiology that modulates neurodegeneration that occurs in Parkinson's disease.
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. bgrimmig@health.usf.edu.
Bethany
B
Grimmig
Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40508, USA. josh.morganti@uky.edu.
Josh
J
Morganti
Byrd Alzheimer's Institute, Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33613, USA. Knash@health.usf.edu.
Kevin
K
Nash
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. pbickfor@health.usf.edu.|James A Haley VA Hospital, 13000 Bruce B Downs Blvd, Tampa, FL 33612, USA. pbickfor@health.usf.edu.
Paula C
PC
Bickford
Parkinson’s disease; astaxanthin; fractalkine; microglia; neuroinflammation
Ann Neurol. 2006 Jul;60(1):65-72
16718702
Eur J Biochem. 2002 Apr;269(8):1996-2002
11985575
J Neurosci. 2012 Oct 17;32(42):14592-601
23077045
J Mol Biol. 2002 Oct 4;322(5):1089-102
12367530
Neurology. 2000 May 23;54(10):1916-21
10822429
Mol Cell Neurosci. 2000 Dec;16(6):724-39
11124893
Ann Neurol. 1988 Oct;24(4):574-6
3239957
Nature. 1988 Jul 28;334(6180):345-8
2899295
Mol Interv. 2010 Oct;10(5):263-70
21045240
J Neurosci. 2015 Jan 14;35(2):807-18
25589773
Mov Disord. 2013 Nov;28(13):1823-31
24123224
Neurobiol Aging. 2013 Jun;34(6):1610-20
23481567
J Neurochem. 2008 Mar;104(6):1504-25
18036154
Neuropharmacology. 2015 Sep;96(Pt A):29-41
25445485
Prog Brain Res. 2010;183:59-77
20696315
Food Chem Toxicol. 2011 Jan;49(1):271-80
21056612
Neuron Glia Biol. 2011 Feb;7(1):77-83
22857738
PLoS One. 2015 Oct 15;10(10):e0140566
26469270
Inflammation. 2015 Aug;38(4):1609-16
25687640
J Microbiol Biotechnol. 2008 Dec;18(12):1990-6
19131704
Ageing Res Rev. 2014 Mar;14:19-30
24503004
J Biol Chem. 2004 Feb 6;279(6):4625-31
14627698
J Clin Biochem Nutr. 2012 Jul;51(1):42-9
22798712
Brain Behav Immun. 2010 Oct;24(7):1190-201
20570721
Neurobiol Aging. 2013 Jun;34(6):1540-8
23332170
Mol Vis. 2013 Jul 25;19:1656-66
23901249
J Neurochem. 2004 Nov;91(3):568-78
15485488
Nat Neurosci. 2013 Dec;16(12):1896-905
24162652
Neuropathol Appl Neurobiol. 2013 Feb;39(1):19-34
23039106
Nat Rev Neurosci. 2011 Jun;12 (6):359-66
21587290
J Neurosci. 2007 Aug 22;27(34):9220-32
17715357
Cell Tissue Res. 2004 Oct;318(1):121-34
15338272
Altern Med Rev. 2011 Dec;16(4):355-64
22214255
Neurochem Res. 2012 Feb;37(2):358-69
21971758
Neuron. 2012 May 24;74(4):691-705
22632727
Neurochem Int. 2015 Aug;87:92-105
26055970
PLoS One. 2013;8(1):e55375
23383169
J Neuroinflammation. 2012 Nov 27;9:259
23186369
Brain Res. 2010 Nov 11;1360:159-67
20828541
Int Immunopharmacol. 2010 Dec;10(12):1560-72
20932499
J Neuroinflammation. 2011 Jan 25;8:9
21266082
J Neurosci. 2014 Sep 10;34(37):12538-46
25209291
Mov Disord. 2013 Mar;28(3):311-8
23436720
Chem Biol Interact. 2010 Aug 5;186(3):306-15
20513374
FASEB J. 2005 Apr;19(6):533-42
15791003
Neurobiol Aging. 2014 Jun;35(6):1442-52
24439957
Mol Neurodegener. 2010 Oct 26;5:42
20977765
Mol Ther. 2015 Jan;23 (1):17-23
25195598
Proc Natl Acad Sci U S A. 2001 Dec 4;98 (25):14669-74
11724929
J Biol Chem. 2014 Aug 1;289(31):21490-507
24942732
J Parkinsons Dis. 2013;3(4):461-91
24252804
Nat Neurosci. 2014 Jun;17(6):832-40
24816140
Exp Neurol. 2012 Jan;233(1):40-8
21110971
Mov Disord. 2006 Jan;21(1):89-93
16108021
BMC Neurosci. 2012 Dec 29;13:156
23272707
J Neurosci. 2013 Jun 12;33(24):10154-64
23761910
Nat Neurosci. 2006 Jul;9(7):917-24
16732273
J Nutr Biochem. 2010 May;21(5):381-9
19423317
J Anim Sci. 2013 Jan;91(1):268-75
23100599
Mol Biol Cell. 2014 Dec 15;25(25):4010-23
25298402
Neurobiol Aging. 2015 Feb;36(2):1110-20
25457558
Cochrane Database Syst Rev. 2011 Nov 09;(11):CD008454
22071848
Brain Res. 2009 Feb 13;1254:18-27
19101523
Cold Spring Harb Perspect Med. 2012 Feb;2(2):a009399
22355802
Cell Calcium. 2010 Feb;47(2):175-82
20053445
PLoS One. 2012;7(9):e45256
23028885
Biochem Pharmacol. 2002 Sep;64(5-6):1037-48
12213603
FEBS J. 2014 Jun;281(12):2838-50
24767583
Neurobiol Aging. 2011 Nov;32(11):2030-44
20018408
Neuroscience. 1990;39(1):151-70
2089275
Neuroscience. 2011 Dec 15;198:221-31
21884755